Elevation Oncology (ELEV) News Today $0.58 -0.05 (-7.30%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Elevation Oncology's (ELEV) Buy Rating Reaffirmed at HC WainwrightDecember 15, 2024 | americanbankingnews.comSynaffix B.V.: Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline ExpansionDecember 12, 2024 | finanznachrichten.deElevation Oncology enters licensing agreement with Synaffix B.V.December 12, 2024 | markets.businessinsider.comElevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline ExpansionDecember 12, 2024 | prnewswire.comElevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid TumorsDecember 12, 2024 | prnewswire.comElevation Oncology presents positive Phase 1 results of EO-3021 combinationDecember 6, 2024 | markets.businessinsider.comElevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024December 5, 2024 | prnewswire.comElevation Oncology to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | prnewswire.comTD Cowen Sticks to Its Buy Rating for Elevation Oncology (ELEV)November 8, 2024 | markets.businessinsider.comElevation Oncology’s Q3 2024 Highlights and Financial ReportNovember 8, 2024 | markets.businessinsider.comElevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business AchievementsNovember 6, 2024 | prnewswire.comEmpery Asset Management's Strategic Acquisition in Elevation OncologyOctober 9, 2024 | gurufocus.comElevation Oncology Gets FDA Fast-Track Designation for EO-3021September 24, 2024 | marketwatch.comElevation Oncology Receives Fast Track Designation For EO-3021 - Quick FactsSeptember 24, 2024 | markets.businessinsider.comElevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2September 23, 2024 | prnewswire.comElevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comElevation Oncology, Inc. (ELEV)August 16, 2024 | finance.yahoo.comInfinyte.Club, HealthCRED, and MiClient Raise Seed FundingAugust 13, 2024 | msn.comElevation Oncology’s EO-3021 Shows Promising Efficacy and Safety in Gastric Cancer, Outperforming Market ExpectationsAugust 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Elevation Oncology (ELEV) and Harmony Biosciences Holdings (HRMY)August 6, 2024 | markets.businessinsider.comWhy Is Penny Stock Elevation Oncology Trading Lower On Tuesday?August 6, 2024 | msn.comElevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical ResultsAugust 6, 2024 | seekingalpha.comElevation Oncology falls after early-stage data for lead cancer drugAugust 6, 2024 | msn.comElevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business AchievementsAugust 6, 2024 | prnewswire.comElevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2August 6, 2024 | prnewswire.comMaintaining Buy Rating on MacroGenics: Assessing Vobra-duo’s Setbacks and Upcoming OpportunitiesAugust 1, 2024 | markets.businessinsider.comBrokers Set Expectations for Elevation Oncology, Inc.'s FY2026 Earnings (NASDAQ:ELEV)Elevation Oncology, Inc. (NASDAQ:ELEV - Free Report) - Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for Elevation Oncology in a report released on Wednesday, July 24th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.80) per shareJuly 26, 2024 | marketbeat.comQ2 2024 Medpace Holdings Inc Earnings CallJuly 24, 2024 | uk.finance.yahoo.comMedpace Holdings, Inc. (MEDP) Q2 2024 Earnings Call TranscriptJuly 24, 2024 | seekingalpha.comElevation Oncology (NASDAQ:ELEV) Earns "Market Outperform" Rating from JMP SecuritiesJMP Securities reiterated a "market outperform" rating and set a $7.00 price objective on shares of Elevation Oncology in a research note on Friday.June 28, 2024 | marketbeat.comElevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction CancerJune 27, 2024 | prnewswire.comStephens & Co. Initiates Coverage of Elevation Oncology (ELEV) with Overweight RecommendationMay 14, 2024 | msn.comElevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of "Buy" from AnalystsElevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) has been given a consensus recommendation of "Buy" by the six research firms that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objectiMay 14, 2024 | marketbeat.comElevation Oncology (NASDAQ:ELEV) Coverage Initiated by Analysts at StephensStephens initiated coverage on shares of Elevation Oncology in a research note on Tuesday. They issued an "overweight" rating and a $8.00 target price on the stock.May 14, 2024 | marketbeat.comElevation Oncology to Present at the Citizens JMP Life Sciences ConferenceMay 7, 2024 | prnewswire.comAnalysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)May 4, 2024 | markets.businessinsider.comElevation Oncology (NASDAQ:ELEV) Given "Outperform" Rating at WedbushWedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Elevation Oncology in a research note on Friday.May 3, 2024 | marketbeat.comHint Health Announces 8th Annual Hint Summit, the Leading DPC Innovation ConferenceMay 2, 2024 | markets.businessinsider.comElevation Oncology GAAP EPS of -$0.23May 2, 2024 | msn.comElevation Oncology Shares Swing to 5% Gain After Extending Cash RunwayMay 2, 2024 | marketwatch.comELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024May 2, 2024 | msn.comElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsMay 2, 2024 | prnewswire.comClariane: First Quarter 2024 RevenueApril 26, 2024 | finance.yahoo.comElevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)April 22, 2024 | seekingalpha.comElevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Up 8.2% in MarchElevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 5,010,000 shares, a growth of 8.2% from the March 15th total of 4,630,000 shares. Currently, 12.6% of the shares of the company are sold short. Based on an average daily volume of 3,060,000 shares, the days-to-cover ratio is currently 1.6 days.April 17, 2024 | marketbeat.comBiologic drug-device combination immunotherapy for metastatic prostate cancer patientsApril 10, 2024 | msn.comPromising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation OncologyApril 9, 2024 | markets.businessinsider.comElevation Oncology (NASDAQ:ELEV) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Elevation Oncology in a research report on Tuesday.April 9, 2024 | marketbeat.comElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024April 8, 2024 | finance.yahoo.comShort Interest in Elevation Oncology, Inc. (NASDAQ:ELEV) Expands By 28.3%Elevation Oncology, Inc. (NASDAQ:ELEV - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 4,630,000 shares, a growth of 28.3% from the February 29th total of 3,610,000 shares. Based on an average daily volume of 2,940,000 shares, the days-to-cover ratio is currently 1.6 days. Approximately 11.6% of the company's stock are short sold.March 30, 2024 | marketbeat.com Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. ELEV Media Mentions By Week ELEV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELEV News Sentiment▼0.340.60▲Average Medical News Sentiment ELEV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELEV Articles This Week▼21▲ELEV Articles Average Week Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PBYI News TIL News ELUT News BDTX News GALT News CGEN News TELO News MNPR News ENTA News ATOS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELEV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
